Page last updated: 2024-11-13

doxoform

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

doxoform: a doxorubicin-formaldehyde conjugate; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID24202589
CHEMBL ID406294
MeSH IDM0332016

Synonyms (5)

Synonym
CHEMBL406294
doxoform
nsc-699490
nsc699490
(7s,9s)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-7-[[4-methyl-1-[[4-methyl-6-[[(1s,3s)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1h-tetracen-1-yl]oxy]-2,3a,4,6,7,7a-hexahydropyrano[4,3-d][1,3]oxazol-1-yl]methyl]-2,3a,4

Research Excerpts

Overview

Doxoform is a prodrug of doxazolidine. It is a monomeric doxorubicin formaldehyde-oxazolidines.

ExcerptReferenceRelevance
"Doxoform is a prodrug of doxazolidine, a monomeric doxorubicin formaldehyde-oxazolidine."( Doxazolidine, a proposed active metabolite of doxorubicin that cross-links DNA.
Barthel, BL; Burkhart, DJ; Hagadorn, JR; Koch, TH; Post, GC, 2005
)
1.05
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID101613compound was tested in vitro for inhibition activity against a sensitive human breast carcinoma line cells.1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Doxoform and Daunoform: anthracycline-formaldehyde conjugates toxic to resistant tumor cells.
AID103085Compound was tested for its toxicity against doxorubicin resistant human breast cancer cells (MCF-7/ADR).1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Epidoxoform: a hydrolytically more stable anthracycline-formaldehyde conjugate toxic to resistant tumor cells.
AID103913Compound was tested for its toxicity against human breast cancer cells(MCF-7)1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Epidoxoform: a hydrolytically more stable anthracycline-formaldehyde conjugate toxic to resistant tumor cells.
AID103093compound was tested in vitro for inhibition activity against doxorubicin resistant counterpart of human breast carcinoma line cells.1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Doxoform and Daunoform: anthracycline-formaldehyde conjugates toxic to resistant tumor cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (60.00)18.2507
2000's1 (20.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.31 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (16.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]